{"schema_version":"secwatch.filing_event.v1","accession":"0001610618-25-000072","form_type":"8-K","ticker":null,"cik":"0001610618","company_name":"Cidara Therapeutics, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.011040+00:00","generated_at":"2026-05-19T01:26:17.094039+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cidara shareholders OK doubling authorized shares to 100M and adding 2.88M shares to equity plan","bullets":["Shareholders approved certificate amendment to increase authorized common shares from 50M to 100M, effective June 18, 2025.","2024 Equity Incentive Plan amended to increase share reserve by 2,880,000 shares; approved by stockholders.","Elected Jeffrey Stein, Bonnie Bassler, and Ryan Spencer as Class I directors for terms expiring at 2028 annual meeting.","Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay passed.","Voting results: Charter amendment 13,042,275 for, 97,601 against; Equity plan 7,791,328 for, 3,033,052 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001610618-25-000072","json":"https://secwatch.observer/filing/0001610618-25-000072.json","markdown":"https://secwatch.observer/filing/0001610618-25-000072.md","text":"https://secwatch.observer/filing/0001610618-25-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/0001610618-25-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/cdtx-20250618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:26:17.094039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22182eee08c32eb1294f05de561de88ea523dfa8","claim":"Cidara Therapeutics, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2025-06-18).","evidence_excerpt":"The increase in the authorized number of shares of Common Stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 18, 2025 and was effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/0001610618-25-000072-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-18"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}